OpGen (OPGN)
(Delayed Data from NSDQ)
$0.56 USD
-0.05 (-8.16%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.56 0.00 (-0.53%) 4:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.56 USD
-0.05 (-8.16%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $0.56 0.00 (-0.53%) 4:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Bright Health Group (BHG) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Bright Health (BHG) delivered earnings and revenue surprises of -63.17% and 61.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Buy 5 Top-Ranked Stocks With Rising P/E in July
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include OpGen (OPGN), Adaptimmune Therapeutics (ADAP), Valmont Industries (VMI), Versus Systems (VS) and Tradeweb Markets (TW).
Bet on DuPont Analysis to Pick 5 Stocks for Stellar Returns
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap PDD Holdings Inc. (PDD), OpGen (OPGN), AGCO (AGCO), A10 Networks (ATEN) and The Duckhorn Portfolio (NAPA).
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), The RealReal (REAL), Trevena (TRVN), ChargePoint (CHPT) and Caterpillar (CAT).
Go Beyond Bargain Hunting, Buy 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include OpGen (OPGN), Horizon Technology Finance (HRZN), Equity Commonwealth (EQC), NOV (NOV) and Spartacus Acquisition (NN).
Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics
by Zacks Equity Research
Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics are part of the Zacks Screen of the Week article.
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
Alignment Healthcare (ALHC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 76.92% and 8.85%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
LHC Group (LHCG) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
LHC (LHCG) delivered earnings and revenue surprises of -25.76% and 3.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 6.25% and 55.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of -31.58% and 2.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -118.75% and 1.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -11.54% and 2.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of 0.00% and -22.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -31.82% and -50.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will OpGen, Inc. (OPGN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates (Revised)
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -20.69% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OpGen, Inc. (OPGN) delivered earnings and revenue surprises of -6.90% and 4.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 13th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Avantor (AVTR) Catches Eye: Stock Jumps 7.8%
by Zacks Equity Research
Avantor (AVTR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Teladoc's (TDOC) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Teladoc's (TDOC) first-quarter earnings gain from higher revenues, partly offset by a rise in expenses.